Who we are
We are a clinical-stage biopharmaceutical company developing
unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on our
proprietary technological platform DOS47.
Our technology
DOS47 is our patented oncology platform technology that offers a new and revolutionary approach to the debilitation and destruction of cancer cells by modulating the tumor microenvironment.
learn more
Patented
Patented oncology
platform technology to
destroy cancer cells
Targeted
Designed to induce an
increase in pH locally at the
site of cancerous cells
Dual Action
Combat tumor acidity and restore immunity
